Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
RESEARCH TOOLSreports
Holding FENC?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.13Last Year’s EPS
0.41Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: 11.92%
|Next Earnings Date:Aug 13, 2018
Earnings Call Sentiment|Positive
The earnings call emphasized the successful expansion of PEDMARK into new market segments, significant sales growth, and strategic leadership changes. However, challenges remain with increased expenses and the need for greater market awareness, particularly in the AYA segment.Company Guidance
During the third quarter of 2024 earnings call for Fennec Pharmaceuticals, Chief Executive Officer Jeff Hackman outlined several key metrics and strategic initiatives aimed at driving future growth for the company. The company recorded net product sales of $7.0 million for the quarter, up from $6.5 million in the same quarter of 2023, contributing to a total of approximately $22 million in net product sales for the first nine months of 2024, surpassing the total for all of 2023. The company achieved greater than 90% reimbursement for PEDMARK in the Adolescent and Young Adult (AYA) population, a significant development considering the potential market of at least 10,000 patients treated annually with cisplatin. Fennec also reported a cash position of approximately $40.3 million, with expectations that current cash reserves will fund operations into at least 2026. Additionally, the company has strengthened its executive leadership team with key appointments, aiming to enhance operational efficiencies and ensure cross-functional alignment. Hackman emphasized the strategic imperatives of increasing awareness, cementing PEDMARK as the standard of care, expanding its adoption across healthcare providers, ensuring seamless access, and activating patient and caregiver engagement.Record Quarterly Sales
For the first 9 months of 2024, the company recorded approximately $22 million in net product sales, exceeding the total net product sales for 2023. The third quarter alone saw $7.0 million in net product sales, compared to $6.5 million in Q3 2023.
Successful Market Expansion and Academic Endorsements
Significant progress in expanding the market for PEDMARK, including emerging proof of concept in the Adolescent and Young Adult (AYA) market segment, with over 90% reimbursement achieved.
Strategic Leadership Appointments
Strengthened executive team with appointments of Pierre Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer.
Partnership with Orsini Specialty Pharmacy
Partnering with Orsini to administer PEDMARK to AYA patients at home, streamlining access and creating a sustainable revenue stream.
International Expansion
Launch plans for PEDMARK in Germany and the UK, expected to provide additional revenue streams in 2025. Successful enrollment of the investigator-initiated trial in Japan, with results expected in 2025.
---
FENC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FENC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $4.95 | $4.36 | -11.92% |
| Aug 13, 2024 | $6.25 | $5.85 | -6.40% |
| May 14, 2024 | $10.02 | $7.34 | -26.75% |
| Mar 21, 2024 | $11.07 | $11.07 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fennec Pharmaceuticals (FENC) report earnings?
Fennec Pharmaceuticals (FENC) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is Fennec Pharmaceuticals (FENC) earnings time?
Fennec Pharmaceuticals (FENC) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FENC EPS forecast?
FENC EPS forecast for the fiscal quarter 2024 (Q4) is -0.13.
---